Yoshiharu Suzuki
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yoshiharu Suzuki has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Haruko Watanabe
Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan
1 shared publicationHirokazu Shimada
Department of Pharmacy, Ibaraki Prefectural Central Hospital, Kasama, Japan
1 shared publication- Kazuhiro Takahashi
Department of Gastrointestinal and Hepato-Biliary-Pancreatic Surgery, Institute of Medicine, University of Tsukuba, Tsukuba, Japan
1 shared publication - Kazunari Kaneko
Department of Pediatrics, Kansai Medical University, Hirakata-Shi, Japan
1 shared publication Keijiro Yabuta
Department of Pediatrics, Juntendo University School of Medicine, Tokyo, Japan
1 shared publication- Kinji Furuya
Department of Gastrointestinal and Hepato‐Biliary‐Pancreatic Surgery Faculty of Medicine University of Tsukuba Tsukuba Ibaraki Japan
1 shared publication
Latest Publications
- 26 December 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 93 (6) , 633-638
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report
Background Guidelines such as the National Comprehensive Cancer Network recommend mycophenolate mofetil (MMF) for the treatment of severe steroid-refractory immune-related hepatotoxicity. Mycophenolic acid (MPA) is an active form of MMF that suppresses T- and B-lymphocyte proliferation and immune-related adverse events caused by immune checkpoint inhibitors. MPA has a narrow therapeutic range (37–70 µg·h/mL) and overexposure increases the risk of leukopenia in transplantation. However, the optimal use of MMF in oncology has not yet been established; thus, monitoring plasma MPA concentrations is necessary to avoid excessive immunosuppression in oncology practice. Case presentation We evaluated plasma MPA concentration in a 75-year-old man with immune-related hepatotoxicity following nivolumab and ipilimumab combination therapy for malignant melanoma. The patient developed severe hepatotoxicity after immunotherapy, and immunosuppressant therapy with corticosteroids was initiated. The patient then developed steroid-refractory immune-related hepatotoxicity; therefore, MMF (1,000 mg twice daily) was co-administered. Seven days after the administration of MMF, the plasma MPA concentration was measured using an enzyme multiplied immunoassay technique. The area under the plasma concentration–time curve for MPA from 0 to 12 h was 41.0 µg·h/mL, and the same dose of MMF was continued. Grade 2 lymphocytopenia, which could be attributed to MMF, was observed during the administration period. Unfortunately, the patient was infected with SARS-CoV-2 and died from respiratory failure. Conclusion Our patient did not exceed the upper limit of MPA levels as an index of the onset of side effects of kidney transplantation and achieved rapid improvement in liver function. Prompt initiation of MMF after assessment of the steroid effect leads to adequate MPA exposure. Therapeutic drug monitoring should be considered when MMF is administered, to avoid overexposure.
- 26 December 2023
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 93 (6) , 633-638
Evaluation of mycophenolic acid exposure in a patient with immune-related hepatotoxicity caused by nivolumab and ipilimumab therapy for malignant melanoma: a case report
Background Guidelines such as the National Comprehensive Cancer Network recommend mycophenolate mofetil (MMF) for the treatment of severe steroid-refractory immune-related hepatotoxicity. Mycophenolic acid (MPA) is an active form of MMF that suppresses T- and B-lymphocyte proliferation and immune-related adverse events caused by immune checkpoint inhibitors. MPA has a narrow therapeutic range (37–70 µg·h/mL) and overexposure increases the risk of leukopenia in transplantation. However, the optimal use of MMF in oncology has not yet been established; thus, monitoring plasma MPA concentrations is necessary to avoid excessive immunosuppression in oncology practice. Case presentation We evaluated plasma MPA concentration in a 75-year-old man with immune-related hepatotoxicity following nivolumab and ipilimumab combination therapy for malignant melanoma. The patient developed severe hepatotoxicity after immunotherapy, and immunosuppressant therapy with corticosteroids was initiated. The patient then developed steroid-refractory immune-related hepatotoxicity; therefore, MMF (1,000 mg twice daily) was co-administered. Seven days after the administration of MMF, the plasma MPA concentration was measured using an enzyme multiplied immunoassay technique. The area under the plasma concentration–time curve for MPA from 0 to 12 h was 41.0 µg·h/mL, and the same dose of MMF was continued. Grade 2 lymphocytopenia, which could be attributed to MMF, was observed during the administration period. Unfortunately, the patient was infected with SARS-CoV-2 and died from respiratory failure. Conclusion Our patient did not exceed the upper limit of MPA levels as an index of the onset of side effects of kidney transplantation and achieved rapid improvement in liver function. Prompt initiation of MMF after assessment of the steroid effect leads to adequate MPA exposure. Therapeutic drug monitoring should be considered when MMF is administered, to avoid overexposure.
- Open Access
- 31 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (17) , 3964
Drug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
Kidney transplant recipients with tacrolimus-based immunosuppressive therapy are often treated with proton-pump inhibitors (PPIs) to prevent gastric ulcer complications. Vonoprazan, a potassium-competitive acid blocker, is a novel PPI possessing different metabolic pathways from conventional PPIs (e.g., omeprazole, lansoprazole and rabeprazole). However, no data are available on the change in blood concentration of tacrolimus after switching rabeprazole, a conventional PPI, to vonoprazan coadministration in the initial period of post-transplantation. This is a retrospective study of 18 kidney transplant recipients. The blood concentration and the concentration to dose (C/D) ratio of tacrolimus were compared before and after switching from rabeprazole to vonoprazan. Impacts of CYP2C19 and CYP3A5 genetic polymorphisms on the drug–drug interaction were also examined. The median (range) trough concentration of tacrolimus was significantly increased from 5.2 (3.6–7.4) to 8.1 (6.1–11.7) ng/mL (p < 0.0005) after switching from rabeprazole to vonoprazan. The C/D ratio of tacrolimus was also significantly increased from 38.1 (16.5–138.1) to 48.9 (26.2–207.2) (p < 0.0005). The percent changes of tacrolimus concentrations and C/D were 65.8% and 41.8%, respectively. CYP2C19 and CYP3A5 genetic polymorphisms did not affect the change in concentration and C/D ratio of tacrolimus. The present study indicates that vonoprazan coadministration increases the tacrolimus concentration regardless of CYP2C19 or CYP3A5 genetic polymorphisms. Thus, frequent monitoring of blood tacrolimus concentration is required when vonoprazan is introduced as an intensive gastric acid blocker in the early phase of post-transplantation.
- 31 August 2021
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 10 (17) , 3964
Open AccessDrug–Drug Interaction between Tacrolimus and Vonoprazan in Kidney Transplant Recipients
Kidney transplant recipients with tacrolimus-based immunosuppressive therapy are often treated with proton-pump inhibitors (PPIs) to prevent gastric ulcer complications. Vonoprazan, a potassium-competitive acid blocker, is a novel PPI possessing different metabolic pathways from conventional PPIs (e.g., omeprazole, lansoprazole and rabeprazole). However, no data are available on the change in blood concentration of tacrolimus after switching rabeprazole, a conventional PPI, to vonoprazan coadministration in the initial period of post-transplantation. This is a retrospective study of 18 kidney transplant recipients. The blood concentration and the concentration to dose (C/D) ratio of tacrolimus were compared before and after switching from rabeprazole to vonoprazan. Impacts of CYP2C19 and CYP3A5 genetic polymorphisms on the drug–drug interaction were also examined. The median (range) trough concentration of tacrolimus was significantly increased from 5.2 (3.6–7.4) to 8.1 (6.1–11.7) ng/mL (p < 0.0005) after switching from rabeprazole to vonoprazan. The C/D ratio of tacrolimus was also significantly increased from 38.1 (16.5–138.1) to 48.9 (26.2–207.2) (p < 0.0005). The percent changes of tacrolimus concentrations and C/D were 65.8% and 41.8%, respectively. CYP2C19 and CYP3A5 genetic polymorphisms did not affect the change in concentration and C/D ratio of tacrolimus. The present study indicates that vonoprazan coadministration increases the tacrolimus concentration regardless of CYP2C19 or CYP3A5 genetic polymorphisms. Thus, frequent monitoring of blood tacrolimus concentration is required when vonoprazan is introduced as an intensive gastric acid blocker in the early phase of post-transplantation.
- Open Access
- 1 January 2004
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 27 (12) , 1907-1912
Endogenous Hyaluronan: A Cytokine-Like Factor Present in Rabbit Uterine Cervix during Pregnancy
The effects of endogenous hyaluronan on cervical ripening during pregnancy were examined in rabbits. Hyaluronan of approximately 620 kilodalton (kDa) was detected in the uterine cervix on the 25th and 29th days of pregnancy, while it was not detected in cervix of non-pregnant animals. In addition, low-molecular-weight (less than 191 kDa) hyaluronan was present in cervix at the 29th day of pregnancy. Hyaluronan level in the cervix was lower on the 29th day than on the 25th day of pregnancy, whereas that in serum was significantly higher on the 29th day than on the 25th day of pregnancy. To clarify the physiological functions of endogenous hyaluronan, the effects of hyaluronan (HA600—700), which had approximately equal to endogenous hyaluronan, on uterine cervical tissues and uterine cervical fibroblasts were examined. Rabbits at the 23rd day of pregnancy were administered a vaginal suppository of HA600—700 (20 mg) daily for three days. Promotion of cervical ripening was observed, as well as detachment of collagen fiber bundles, and a reduced density of collagen fiber distribution. Total collagenolytic activity was increased significantly by HA600—700 (1.0 mg/ml) treatment in cultured uterine cervical explants of pregnant rabbits as compared with the untreated group. Moreover, very similar effects of HA600—700 treatment (0.1, 1.0 mg/ml) were observed in cultured uterine cervical fibroblasts. Further, in tissue cultures, but not cell cultures, of pregnant rabbit cervix, prostaglandin E2 (PGE2) production was enhanced by HA600—700 treatment. Therefore, it appears that endogenous hyaluronan is closely concerned with cervical ripening and dilatation in uterine cervix of pregnant rabbits.
- 1 January 2004
- Published by Pharmaceutical Society of Japan in Biological and Pharmaceutical Bulletin
- Vol. 27 (12) , 1907-1912
Open AccessEndogenous Hyaluronan: A Cytokine-Like Factor Present in Rabbit Uterine Cervix during Pregnancy
The effects of endogenous hyaluronan on cervical ripening during pregnancy were examined in rabbits. Hyaluronan of approximately 620 kilodalton (kDa) was detected in the uterine cervix on the 25th and 29th days of pregnancy, while it was not detected in cervix of non-pregnant animals. In addition, low-molecular-weight (less than 191 kDa) hyaluronan was present in cervix at the 29th day of pregnancy. Hyaluronan level in the cervix was lower on the 29th day than on the 25th day of pregnancy, whereas that in serum was significantly higher on the 29th day than on the 25th day of pregnancy. To clarify the physiological functions of endogenous hyaluronan, the effects of hyaluronan (HA600—700), which had approximately equal to endogenous hyaluronan, on uterine cervical tissues and uterine cervical fibroblasts were examined. Rabbits at the 23rd day of pregnancy were administered a vaginal suppository of HA600—700 (20 mg) daily for three days. Promotion of cervical ripening was observed, as well as detachment of collagen fiber bundles, and a reduced density of collagen fiber distribution. Total collagenolytic activity was increased significantly by HA600—700 (1.0 mg/ml) treatment in cultured uterine cervical explants of pregnant rabbits as compared with the untreated group. Moreover, very similar effects of HA600—700 treatment (0.1, 1.0 mg/ml) were observed in cultured uterine cervical fibroblasts. Further, in tissue cultures, but not cell cultures, of pregnant rabbit cervix, prostaglandin E2 (PGE2) production was enhanced by HA600—700 treatment. Therefore, it appears that endogenous hyaluronan is closely concerned with cervical ripening and dilatation in uterine cervix of pregnant rabbits.
- 1 January 1995
- Published by S. Karger AG in Nephron
- Vol. 69 (1) , 102-103
Membranoproliferative Glomerulonephritis in a Child with Liver Cirrhosis
- 1 January 1995
- Published by S. Karger AG in Nephron
- Vol. 69 (1) , 102-103
Membranoproliferative Glomerulonephritis in a Child with Liver Cirrhosis